TUESDAY, DECEMBER 8, 2015(continued)
EVENING SESSION15:30–17:00
Poster Session 17:00
Review of Poster Presentations
Adrian Di Bisceglie;
Saint Louis University School of Medicine, USA
Matthias Götte
University of Alberta, Canada
THE TIDE HAS SHIFTED TOWARD HBV CURE AND TREATMENT FOR NASH
Chairs:
Patrizia Farci; National Institutes of Health, USA
Stanley Lemon;
University of North Carolina at Chapel Hill, USA
17:50
Using CRISPR/C as to Cure Chronic HBV Infections
Bryan Cullen; Duke University Medical Center, USA
18:10
Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, For the Treatment of Hepatitis B
John Sullivan-Bὀlyai; ContraVir Pharmaceuticals, Inc., USA
18:20
Cyclophilin Inhibitors and Their Potential as Therapeutics for the Treatment of HBV
Michael Sofia; Arbutus Biopharma Corporation,USA
18:30
Preclinical and Clinical Profile of NVR 3-778, a First-In-Class HBV Core Inhibitor for the Treatment of Chronic Hepatitis B
Osvaldo Flores; Novira Therapeutics,USA
18:40
New Insights on HBV Biology from the ARC-520 Development Program
Bruce Given;Arrowhead Research Corporation, USA
18:50
Cenicriviroc: A Novel Agent Targeting Immuno-Inflammatory Pathways for the Treatment of NASH with Liver Fibrosis
Eric Lefebvre;Tobira Therapeutics, Inc., USA
19:00
RG-101, a Novel microRNA Therapeutic to Target the Host Factor of HCV
Paul Grint; Regulus Therapeutics, USA
19:10 The Clinical Stage Molecule Birinanant Can Harness Endogenous TNF to Kill HBV Infected Hepatocytes and Clear Infection in a Preclinical Model
Marc Pellegrini; The Walter and Eliza Hall Institute of Medical Research, Australia作者: StephenW 时间: 2015-11-20 17:17
